RFK Jr. Ends mRNA Funding, Sarepta Beats Q2…

Aug 8

Biotech Q2 round-up: Sarepta rebounds, Eli Lilly’s oral GLP-1 disappoints, and U.S. vaccine strategy pivots away from mRNA (August 1–7, 2025).

Read →

Comments

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Biotech Blueprint

RFK Jr. Ends mRNA Funding, Sarepta Beats Q2…